Edition:
United Kingdom

Profile: GNI Group Ltd (2160.T)

2160.T on Tokyo Stock Exchange

3,120JPY
7:00am BST
Change (% chg)

¥5 (+0.16%)
Prev Close
¥3,115
Open
¥3,170
Day's High
¥3,200
Day's Low
¥3,085
Volume
108,000
Avg. Vol
194,088
52-wk High
¥5,010
52-wk Low
¥2,506

GNI Group Ltd. is a Japan-based company engaged in new drug production activities utilizing biotechnologies. The Company is engaged in the development of therapeutic agents for diseases that have many sufferers in Asian countries such as Japan and China, as well as clinical trial and bio-verification test businesses. It is engaged in research and development of therapeutic agents, including F647 for radiation pneumonia (RP) and idiopathic pulmonary fibrosis (IPF), F351 for liver fibrosis (cirrhosis) and F573 for acute hepatic insufficiency and acute chronic liver failure (ACLF).

Company Address

GNI Group Ltd

3F, Nihonbashi-Honcho YS Bldg
2-2-2, Nihonbashi Hon-cho
CHUO-KU   TKY   103-0023
P: +813.62143600
F: +813.62143668

Company Web Links